Skip to main content

24 Lawyers In Leadership Roles Identified For Zantac Lawsuits

24 Lawyers In Leadership Roles Identified For Zantac Lawsuits

24 Lawyers In Leadership Roles Identified For Zantac Lawsuits

Introduction

The U.S. District Judge conducted virtual online interviews of more than 60 attorneys to choose 24 plaintiffs' lawyers for the proceedings of Zantac lawsuits.

According to research, the use of Zantac has side effects on the users like exposure to cancer. Sanofi the manufacturing company of Zantac currently faces 200 product liability lawsuits with similar allegations that the drug has developed breast cancer, testicular cancer, kidney cancer, bladder cancer, stomach cancer, or other injuries to the plaintiffs.

It is estimated that more thousand claims of the Zantac lawsuits will be filed in the coming year against the company. The lawsuits claim that ranitidine, an active ingredient in Zantac, produces high levels of the known human carcinogen Nitrosodimethylamine (NDMA), and the drug makers are aware of it.

In February 2020, all the Zantac lawsuits were centralized before the U.S. District Judge Robin L. Rosenberg in the Southern District of Florida to avoid duplicative discoveries and multiple individual trials.

Due to the ongoing COVID-19 pandemic, Judge Rosenberg was forced to conduct virtual interviews of 63 lawyers for the proceedings of the trials in the Zantac MDL. According to a pretrial order issued on May 8, Judge Rosenberg identified a group of 24 attorneys from law firms nationwide, which included four co-lead counsels, one liaison counsel, 15 members of a Plaintiffs’ Steering Committee (PSC), and five lawyers to serve on a leadership development committee.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!